Lia DeGroot

The FDA late Fri­day fi­nal­ized new re­quire­ments for safe­ty la­bel­ing on new opi­oid pain med­ica­tions, mark­ing progress in the agency’s ef­fort to crack down on

Fol­low­ing FDA ap­proval, Ver­tex Phar­ma­ceu­ti­cals and CRISPR Ther­a­peu­tics on Fri­day re­ceived a pos­i­tive rec­om­men­da­tion for a con­di­tion­al ap­proval by a key Eu­ro­pean med­i­cines pan­el for

RSV vac­cine man­u­fac­tur­ers Sanofi and As­traZeneca will make 230,000 more dos­es of their im­mu­niza­tions for in­fants avail­able be­gin­ning in Jan­u­ary to ad­dress high de­mand, the

The House on Mon­day evening passed a wide-rang­ing bill that aims to make the health­care in­dus­try more trans­par­ent, in­clud­ing amp­ing up re­port­ing re­quire­ments for in­sur­ers

The FDA is as­sem­bling a new ad­vi­so­ry com­mit­tee to eval­u­ate po­ten­tial treat­ments for ge­net­ic meta­bol­ic dis­eases, the agency an­nounced Tues­day. Ge­net­ic meta­bol­ic dis­eases are typ­i­cal­ly

A bi­par­ti­san duo of law­mak­ers is seek­ing to boost pe­di­atric drug de­vel­op­ment with new leg­is­la­tion that would pri­or­i­tize adding pe­di­atric pa­tients to tri­als for new

The glob­al health part­ner­ship Gavi is look­ing to ramp up vac­cine ac­cess in Africa through a slate of pro­grams that puts up $1.8 bil­lion to

The House En­er­gy & Com­merce Com­mit­tee on Wednes­day ad­vanced sev­er­al pieces of leg­is­la­tion seek­ing to re­quire more trans­paren­cy from phar­ma­cy ben­e­fit man­agers, mov­ing them one

Pfiz­er is plan­ning to leave the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion, a source fa­mil­iar with the mat­ter con­firmed to End­points News, as it will not re­new its

The gener­ic drug mar­ket took cen­ter stage Tues­day at a Sen­ate Fi­nance Com­mit­tee hear­ing on drug short­ages as law­mak­ers on Capi­tol Hill work to rem­e­dy